Burggraben stocks identified as heavily discounted by Morningstar
In the latest evaluation by Morningstar, a selection of high-quality moat stocks have been identified, offering investors a potential opportunity for long-term growth. Among these undervalued moat stocks are Estee Lauder, Bristol-Myers Squibb, and Nike.
Estee Lauder (EL) is a global cosmetics powerhouse with a market cap of approximately $32 billion and revenues nearing $15.6 billion as of 2025. Listed within the Fortune 500, Estee Lauder is a stable player in the industry, showing moderate strength with a stock price of $89.82, up by 1.29% recently. The company's strong brand loyalty and global reach make it an attractive investment, with its stock holding key support levels according to moving average analysis.
Bristol-Myers Squibb (BMY), a major player in the pharmaceutical industry, boasts revenues of around $48.3 billion and a stock price of $47.21. Its defensive moat, stemming from patent-protected drug portfolios and a large R&D base, makes it a steady investment. Moving average analysis suggests a stable or slow upward trend, indicating long-term accumulation phases.
Though not explicitly detailed in the search results, Nike (NKE) is a well-known moat stock with a global brand and strong economic moat in apparel and footwear. As a large-cap S&P 500 member, Nike's investment thesis often involves strong return on invested capital (ROIC) and resilient pricing power. Its price action typically respects key moving averages like the 50- and 200-day lines.
These undervalued moat stocks represent quality investment ideas for long-term investors, according to Morningstar. To gain a clearer understanding of Morningstar's latest analyst ratings or detailed moving average trends, direct access to their platform or specific technical analysis reports may be necessary. However, the combination of Fortune 500 status, market cap, revenue, and recent price stability suggests that these stocks are worth considering for investors seeking moat stocks with long-term competitive advantages.
In addition to these three companies, Morningstar has identified ten undervalued moat stocks: Zimmer Biomet, Pfizer, Nike, Boeing, NXP Semiconductors, Bio-Rad Laboratories, Bristol-Myers Squibb, Alphabet, and Veeva Systems. The BÖRSE ONLINE editorial team also provides exclusive stock tips in their Outperformance Newsletter.
As always, investors are encouraged to conduct thorough research and consider their own investment objectives and risk tolerance before making any investment decisions.
Read also:
- Deepwater Horizon Oil Spill: BP Faces Record-Breaking Settlement - Dubbed 'Largest Environmental Fine Ever Imposed'
- Lawsuit of Phenomenal Magnitude: FIFA under threat due to Diarra's verdict, accused of player injustice
- Expansion of railway systems, implementation of catenary systems, and combating fires: SNCF adapting to the summer heatwave
- Citizen Thekla Walker, Minister, advises: "Let's focus on our own homes first"
